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Abstract
This review is focused on the most recent knowledge on growth control of rat thyroid cell lines. We
analyzed the effect of mitogenic as well as inhibitory agents, but mainly the proliferative effect elicited
by thyrotropin (TSH). The classic cAMP-dependent protein kinase (PKA) signal transduction pathway
involved in TSH-mediated cell growth is analyzed exhaustively. We have also reviewed new concepts
about the participation of other effectors such as small GTPases and phosphatidyl inositol-3-kinase
(PI3-K) and the new data about the existence of a cAMP-dependent but PKA-independent pathway.
Finally, we give information about TSH induction of cell cycle-related genes, such as G1 cyclins, cyclin-
dependent kinases (CDKs) and CDK inhibitors.
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Introduction
The different extracellular signals that activate prolif-
eration in mammalian cells are coordinated with the
cell cycle machinery by different transduction path-
ways. This activation process involves transcriptional
and post-transcriptional events that ®nally overpass the
®rst GTPase-activating protein (GAP) (G1 phase) and
initiate DNA synthesis (S phase). Key regulators of G1
progression include the D- and E-type cyclins, which
respectively assemble with cyclin-dependent kinases
(CDK)-4/6 during G1 or with CDK-2 at the G1±S
boundary. The activation of CDKs, by binding to G1
cyclins, promotes the phosphorylation of necessary
substrates like retinoblastoma (Rb) protein. In the
absence of phosphorylation, Rb will negatively regulate
the activities of transcription factors implicated in cell
cycle control like E2F±DP1 heterodimers, which are
essential for the G1±S transition. Alternatively, cyclin±
CDK complexes can be inhibited by two families of
cyclin-dependent kinase inhibitors de®ned by their
structural homology and CDK targets. The ®rst family
includes the inhibitor kinase (INK) proteins that
speci®cally bind and inhibit CDK4 and CDK6 but not
other CDK or cyclins. The INK family includes four
proteins with multiple ankyrin repeat sequences: p16INK4a
(1), p15INK4b (2), p18INK4c (3, 4), and p19INK4d (4, 5). This
family contrasts with more broadly acting inhibitors, the
Cip/Kip family, whose action affects the activities of E and A
cyclin-dependent CDK2 and positively regulates D cyclin-
dependent kinase (6). The Cip/Kip family includes p21Cip1
(7±12), p27Kip1 (13, 14), and p57Kip2 (15, 16), all of
which have characteristic motifs that enable them to
bind to cyclin as well as to CDK subunits (17±22).
This review is focused on in vitro experimental models
of rat thyroid cell lines including the Fisher rat (FRTL-5)
(23), the Wistar rat (WRT) (24) and PC C13 (25) cell
lines. Although the FRTL-5 cell line is the most fre-
quently used system, all of them retain most of the
features of differentiated follicular thyroid cells, such as
thyrotropin (TSH)-dependence for growth and function,
iodine uptake, and thyroglobulin (Tg) and thyroper-
oxidase (TPO) gene expression. The simplicity of these
systems allows stable transfections and genetic experi-
ments and also explains why they are the preferred
models in most of the in vitro studies of thyroid biology.
The second part of this review is focused on the more
recent advances in our understanding of the mitogenic
effects of TSH, the signal transduction pathways
involved in this response, including the role of the
Ras superfamily, and its effects on the main cell cycle-
related genes. Thus, classically, binding of TSH to the
TSH receptor (TSH-R) stimulates both growth and
function of thyroid cells. TSH-R coupled to adenylyl
cyclase elevates cAMP levels promoting the activation of
cAMP-dependent kinase (PKA) and the consecutive
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phosphorylation of transcription factors such as cAMP
response element binding (CREB) proteins. This phos-
phorylation is required to activate the expression of
important genes implicated in normal growth and
phenotype differentiation in thyroid cells (26). We have
also reviewed the role of the small GTPases involved in
TSH-mediated proliferation and found that the classic
view summarized above now seems to be more complex.
Thus, TSH-mediated proliferation requires Ras activa-
tion but not through typical Ras effectors such as Raf-1/
mitogen-activated protein kinase (MAPK). Some evi-
dence indicates that other Ras effectors, such as RalGDS
(Ral GDP dissociation stimulator), phosphatidylinositol-
3-kinase (PI3-K) or members of the Rho family, could
be involved in the TSH actions. These observations,
together with the new characterization of a family of
cAMP-binding proteins that directly activate Rap1,
open a new ®eld of study on the role of these proteins
in the thyroid. In this way, recent results suggest the
need to reformulate concepts about cAMP-mediated
signalling. Finally, we go over the effect of TSH on the
cell cycle machinery. Thus, TSH induces cell cycle-
related gene expression such as G1 cyclins (D1, D3 and
cyclin E) and CDK2, as well as down-regulates the
universal CDK inhibitor p27Kip1. The resulting increases
are re¯ected by an elevation in the hyperphosphorylated
form of Rb.
Rat thyroid cell systems
There is a broad range of in vitro models for studying
thyroid growth and function. We can distinguish
between primary cell cultures and established cell
lines. Both have been widely used and have some
advantages and handicaps, basically in the comparison
of in vitro and in vivo situations, although the accumu-
lated data proceeding from both experimental
approaches should help to obtain a clearer view of
thyroid physiology. The most frequently used rat cell line
is FRTL-5 (23), which was obtained from a primary
culture from 5- to 6-week-old rats of the NIH Fischer
344 inbred strain. Rat thyroid glands were excised, cut
into small pieces and digested using standard methods
for the isolation of primary cell lines (27, 28). Cells were
cultured in a modi®ed Ham's F-12 medium (29)
supplemented with 0.1±0.5% donor calf serum and a
hormone mixture, derived from the initial cocktail from
Hayashi & Sato (30) including 10 ng/ml glycyl-L-
histidyl-L-lysine, 5 mg/ml transferrin, 10 nM hydrocorti-
sone, 10 ng/ml somatostatin, 10 mg/ml insulin, and
1 nM TSH. Primary culture was done in a low serum
medium to avoid the selection of ®broblast-like cells,
which are better adapted to growth in conventional
culture conditions. The primary thyroid culture was
completely dependent on TSH and insulin for growth
and survival. Thus, the persistence of morphological
and differentiated characteristics of the cells was
dependent on TSH dose starting with 0.5 mU/ml, and
maximal growth stimulation was obtained between 5.0
and 10.0 mU/ml.
The original FRTL strain grows with a doubling time
of 5±7 days in the above-de®ned medium. The cells
remain diploid with 42 chromosomes and the morpho-
logical characteristics of the primary FRTL culture
remains unchanged. The individual cells are small with
a small nucleus containing one or two nucleoli. The
cells tend to grow in groups, forming follicle-like
structures that grow on top after several weeks in
culture, rather than expanding in a monolayer to ®ll
the empty spaces on the dish. These cells maintain
highly differentiated features typical of the thyroid
phenotype such as Tg and TPO synthesis, iodine uptake
and hormone dependence. Low serum conditions were
critical during early passages, when the more differ-
entiated cells are selected. Once isolated, a sub-strain of
FRTL cells was grown in Ham's F-12, Coon's modi®ed
medium plus the six hormone mixture and 5% serum
(complete medium). These cells were called FRTL-5
cells, had a doubling time of 30±40 h and remained
diploid and differentiated (23, 31±34). The continuous
presence of TSH is a necessary requirement for cellular
growth. Thus, removing TSH from the culture medium
arrests cellular replication and this arrest is reversed
by the readdition of TSH. Cell growth then resumes with
a 2 day `lag phase' in the continued presence of TSH
(32). Insulin alone is not a growth factor for FRTL-5
cells, but its removal from the complete medium
signi®cantly reduces the growth rate (23). Insulin
appears to be a permissive factor in TSH stimulation of
FRTL-5 cell growth (35). None of the other factors
present in the complete medium is a mitogen by itself,
or can positively in¯uence TSH-dependent cellular
growth.
Other rat thyroid cell lines isolated by similar
methods are the WRT (Wistar rat thyroid) (24) and
the PC C13 cell lines (25) (Table 1). The main
difference among these systems is the selection by
cellular cloning from ®broblasts in the case of WRT and
PC C13, versus selection by a low concentration of calf
serum in the case of the FRTL cells. In addition, PC C13
cells were obtained from 18-month-old rats whereas
WRT cells were obtained from 3- to 4-week-old rats.
Furthermore, insulin itself acts as a mitogen in WRT
cells whereas in the FRTL-5 and PC C13 cells it is a
permissive factor (35, 36). All are immortal cell lines
from primary rat thyroid cultures which are con-
sidered `normal': the cells are euploid, they do not
grow in soft agar, do not show contact inhibition, and
are not tumorigenic in euthyroid nude mice, although
they can become tumorigenic when circulating TSH
levels are arti®cially elevated after chemical destruc-
tion of the thyroid gland with Na131I (37) or after
goitrogenic drug administration (38). The character-
istics of the most useful rat thyroid cell lines appear in
Table 1.
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Extracellular signals involved in the control of
thyroid cell proliferation
TSH, insulin and IGF-I The main regulators of thyroid
growth and function (39) are TSH and insulin, which
recognize both insulin- and IGF-I receptors. Both can
produce a dose-dependent increase in DNA synthesis
and cell proliferation. When added together, insulin and
TSH cooperate synergistically inducing a level of
proliferation that is much greater than the sum of the
effects of each one alone (23, 24, 36). In PC C13 and
FRTL-5 cells, insulin and TSH activate both growth in
size and DNA replication (36). In FRTL-5, TSH alone
promotes proliferation but this effect can be masked by
the presence of the cytostatic agent somatostatin in the
culture medium (40). Submitogenic concentrations of
insulin (50 ng/ml) greatly potentiate the TSH effects in
FRTL-5, PC C13, and WRT cells suggesting, once more,
that insulin acts as a permissive factor for TSH action.
Thus, it is possible to distinguish two major pathways
stimulated at the level of the TSH-R or at the level of the
insulin or IGF-I receptor.
TSH recognizes speci®c receptors on the thyrocyte
surface and triggers the activation of adenylyl cyclase
and other effectors via the heterotrimeric guanine
nucleotide-binding protein (G-protein) (41). TSH-R
belongs to a broad class of G-protein-coupled receptors.
The basic structure of these receptors shows three
domains: an extracellular segment at the N-terminus
where the hormone binds, seven transmembrane
helices, and three intracellular loops at the C-terminus
(42, 43). Several experimental approaches demon-
strated that the TSH-mediated response involves the
activation of adenylyl cyclase and the increase of
intracellular cAMP levels (39, 44). cAMP is the main
second messenger in thyroid cells; thus agents which
increase cAMP intracellular levels, such as forskolin or
8-bromo-cAMP, stimulate the expression of thyroid-
speci®c genes, iodine uptake, the synthesis and secretion
of thyroid hormones, and the growth of thyroid cells
(34, 45, 46). In FRTL-5 cells, this second messenger
stimulates both DNA synthesis and cell proliferation,
and increases the levels of proto-oncogene mRNAs such
as c-myc and c-fos (47, 48). In WRT cells, the micro-
injection of an antibody for the stimulatory G-protein of
adenylate cyclase Gs inhibits TSH-induced DNA syn-
thesis (49). The importance of the TSH-R and cAMP-
dependent pathway in the control of thyroid cell
proliferation is also demonstrated by the observation
that TSH-R gene mutations, which constitutively
activate this receptor, have been associated with the
development of thyroid tumors. Thus, mutations in the
TSH-R gene have been observed in human adenomas
and in congenital hyperthyroidism (50±56). These
mutations in the TSH-R gene permanently activate
adenylyl cyclase leading to TSH-independent prolifera-
tion and to constitutive cAMP accumulation, as well as
phosphatidylinositide pathway activation in some cases
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(57). Furthermore, the overexpression of TSH-R mutant
proteins in FRTL-5 cells induce neoplastic transforma-
tion (58). Together, all these ®ndings clearly suggest
that the effects of TSH through its receptor are mainly
due to increased intracellular cAMP levels.
The facts that insulin effects on thyroid cell growth
are observed at pharmacological doses and mimicked by
physiological doses of IGF-I suggest that insulin could
act through the IGF-I receptors (59, 60). These receptors
are glycoproteins that include two extracellular a-sub-
units which bind the ligand and two b-subunits with an
intrinsic tyrosine kinase activity on their intracellular
domain (61). After insulin stimulation tyrosine kinase
activity promotes the autophosphorylation of the recep-
tor and other proteins such as insulin receptor substrates
(IRS), Vav proto-oncogen, and adapter molecules such
as Shc (62). These events activate signal transduction
pathways, such as Ras/MAPK, PI3-K, and PKC (63±
65), that ®nally regulate insulin target genes. There are
several indications of a role for PKC in insulin action in
FRTL-5 and PC C13 cells. Both insulin and TSH induce
the synthesis of 1,2-diacylglycerol, the endogenous
activator of PKC (66), while PKC activators such as the
phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate
(TPA) mimic the effects of insulin in both cell lines. In
fact TPA in PC C13 cells seems to be almost as potent as
insulin (36, 67). In addition, co-stimulation with insulin
and TPA in FRTL-5 or PC C13 cells does not synergize
proliferation or protein synthesis, suggesting that both
compounds activate the same pathway.
Together with insulin and IGF-I, there are several
other growth factors that may also activate proliferation
via mechanisms that are triggered by the activation of
the tyrosine kinases (68, 69). Some of these factors have
an autocrine effect on proliferation (70, 71). Thus,
although it has been suggested that FRTL-5 cells lose
the epidermal growth factor (EGF) response (39),
recently Kimura et al. (36) reported a slight increase
in [3H]thymidine-labeled nuclei after EGF or hepatocyte
growth factor (HGF) stimulation in FRTL-5 cells, and
this increase was potentiated by insulin. Conversely, PC
C13 cells do not respond to EGF or HGF (36).
Other growth factors and local signals Epithelial cell
proliferation is controlled by extracellular signals that
include a variety of regulator peptides. Some of these
factors are synthesized and released by the epithelial
cells themselves and they act as an essential part of an
autocrine mechanism. It is thought that the regulatory
function of these factors mediates or modi®es the local
action of classic hormones. Thus, the TSH-mediated
proliferation of thyrocytes might partially be due to the
release and autocrine effects of these growth-promoting
factors (72). The following are some of the growth
factors associated with TSH-mediated proliferation.
ATP. The purinergic agonist ATP is a potent activator of
the phosphatidylinositol 4,5-biphosphate/inositol-1,4,5-
triphosphate (PIP2/IP3) signal transduction pathway
(73±76). In FRTL-5 cells, the activation of this pathway
results in a substantial increase in intracellular free
calcium levels. ATP acts as a potent co-mitogen in these
cells, enhancing the incorporation of [3H]thymidine in
the presence of insulin and TSH. This effect appears to
be mediated by the activation of a MAPK pathway,
although the mechanism of this activation remains
unknown (77).
Sphingolipid metabolites. Sphingosine-1-phosphate (SPP)
mobilizes sequestered calcium and stimulates prolifera-
tion in several different cell types. In FRTL-5 cells SPP
rapidly mobilizes and sequesters calcium, which stimu-
lates the entry of extracellular calcium and hereby
increases the incorporation of [3H]thymidine in a dose-
dependent manner (78).
Amyloid peptides. The proteolytically released ecto-
domain of the b-amyloid precursor protein (APP) (72)
is a single membrane-spanning glycoprotein known to
serve as the macromolecular precursor for the amyloid
peptide found in senile plaques and neuro®brillar
tangles in the cerebral cortex of patients affected with
Alzheimer's disease (79). APP is almost ubiquitously
expressed and shows a high degree of evolutionary
conservation (80, 81). Popp et al. (72) have demon-
strated that APP promotes the growth of FRTL-5 cells
and that the TSH-mediated proliferation might be
related in part to APP activity.
Iodine. This element has an autoregulatory effect on
various aspects of thyroid function and metabolism.
Iodine de®ciency may render a normal TSH concentra-
tion goitrogenic (39). Iodine inhibits thyroid growth
and this is one of its major autoregulatory effects on this
gland. This inhibition appears to be mediated by iodine
interference with TSH-induced cAMP production
although other inhibitory mechanisms may be involved
(82). In addition, high iodine concentrations arrest the
cell cycle at the G1 and G2±M phases, thus inhibiting
FRTL-5 cell proliferation (83).
Other negative autocrine factors TGF-b. Transform-
ing growth factor b (i.e. three closely related isoforms
TGF-b1, -b2 and -b3) is a multifunctional cytokine with
diverse biological actions that in¯uence a wide range of
cellular, physiological, immunological and developmen-
tal processes (84, 85). TGF-b is the most potent inhibitor
of in vivo and in vitro growth for a wide variety of cell
type. Expression of TGF-b precursor mRNA has been
detected in most cell types, suggesting that it may
mediate a negative autocrine loop that limits normal
cell proliferation. TGF-b1 has been found to inhibit
proliferation in all the normal thyroid cell systems and,
in some of these systems (86), it also prevents thyroid
speci®c differentiation. On the other hand, TGF-b1
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precursor mRNA and/or immunoreactivity have been
found in various pathological thyroid tissues, including
follicular adenomas and malignant thyroid tumors (87).
One example of the role of TGF-b1 in the control of
proliferation appears in thyroid hyperplasia during the
development of a goiter when thyroid follicular cells
proliferate in response to a goitrogen (for review see 88).
When the thyroid has reached a certain size, growth
stops despite continuous administration of the goitrogen
and this effect is accompanied by a wide-spread
expression of TGF-b1 in the entire follicular epithelium;
in normal thyroid the effect is restricted to parafollicular
C cells (89). Withdrawal of the goitrogen results in a
reduction in size of the thyroid gland that is partly
mediated by cell death (39). This process correlates with
high levels of TGF-b1 expression, suggesting that it
plays a role in thyroid apoptosis. As in the in vivo
situation, FRTL-5 growth is also inhibited by TGF-b1 in
several physiological conditions. Thus, TGF-b1 induces
apoptosis in quiescent cells and arrests growth in
proliferating cells that are not stimulated by the
presence of a stronger mitogenic stimulus such as TSH
or TSH plus IGF-I (90±92). In all these situations TGF-
b1 decreases p27Kip1 mRNA, cyclin D1, cyclin E±CDK2
activity and retinoblastoma phosphorylation. On the
other hand, TGF-b1 increases p15 and c-myc mRNA
expression (92). These ®ndings suggest a physiological
role for TGF-b1 in the control of thyroid growth through
the modi®cation of cell cycle regulatory proteins. In
addition, Morris et al. (91) found that TSH stimulates
the production of a TGF-b-like activity by FRTL-5 cells.
This observation provides a good in vitro cell system to
study the mechanism of TGF-b action in the control of
thyroid proliferation.
Somatostatin. Somatostatin was initially identi®ed as a
potent growth hormone (GH) inhibitor in the hypo-
thalamus. Soon after, it was identi®ed in many tissues
and cell lines exerting different biological actions,
including inhibition of hormone secretion processes,
control of neural cognitive and locomotor functions,
and regulation of cell proliferation (93, 94). Somato-
statin has also been found in the thyroid, more
speci®cally in parafollicular C cells, leading to the
speculation that this peptide could have local effects on
thyroid hormone release, as well as a local action as a
paracrine peptide (95). In FRTL-5 cells, somatostatin
inhibits TSH- and IGF-I-mediated proliferation (96).
More recently, the effect of somatostatin on cell
proliferation has also been characterized in PC C13. In
these cells, somatostatin inhibits insulin-dependent and
insulin plus TSH-dependent cell growth, blocking the
G1±S transition of the cell cycle (97). Somatostatin
action is mediated by at least six different subtypes of
receptors (called SSTR-1, -2A, -2B, -3, -4, and -5) (98).
These receptors, belonging to the seven transmembrane
domain superfamily, are coupled to different G-proteins
that link SSTR to distinct cellular effector systems, such
as adenylyl cyclase, protein tyrosine phosphatases, and
the K+ and Ca2+ channels. They are responsible for the
broad spectrum of somatostatin actions. Overexpression
of SSTR-2 in several cell lines inhibited growth and
increased the expression of preprosomatostatin mRNA
accompanied by somatostatin secretion (98). In addi-
tion, SSTR expression correlated with the constitutive
activation of a tyrosine phosphatase (99). Furthermore,
somatostatin increased SSTR mRNA in a pitutary cell
line (100). More recently, we provided evidence that
somatostatin is also expressed in FRTL-5 cells and its
transcription is under the control of TSH. Experiments
with conditioned medium from TSH-treated FRTL-5
cells demonstrate that this peptide has a cytostatic effect
on cell growth that promotes cell cycle arrest at the G1
phase. Somatostatin action is mediated by the cyclin-
dependent kinase inhibitor p27Kip1, which is down-
regulated by TSH to promote proliferative signals. These
®ndings suggest that, within thyroid follicular cells,
somatostatin expression is a local mechanism that
regulates cell growth in an autocrine fashion (40).
Signal transduction pathways
So far, we have described the main growth factors
and inhibitory signals that control the complex regu-
lation of thyrocyte proliferation. These factors exert
their functions by activating several signal transduction
pathways. Perhaps, as we have stated before, the TSH±
cAMP±PKA pathway may be the most important signal
in the control of thyroid growth and function but there
are other pathways that have been implicated in this
regulation, PKC, MAPK and, recently, the PI3-K path-
way. In summary, control of thyroid growth and
function involves PKA-dependent and -independent
pathways.
PKA
The cAMP-dependent PKA is held to mediate cAMP
action. There are at least two types of PKA enzymes,
PKAI and PKAII, each has a different cellular location,
species and tissue distribution, as well as cAMP af®nities
(101). PKAI is a soluble cytoplasmic enzyme (102),
while PKAII, a and b, are often associated with the
cytoskeleton and Golgi apparatus, centrosomes and the
perinuclear area (103±105). The regulation and
localization of the catalytic (C) subunit of PKA is
typically mediated through interaction with an inhibi-
tory regulatory (R) subunit, which sequesters the C
subunit in an inactive state under physiological condi-
tions (106±109). The inactive holoenzyme is a hetero-
tetramer composed of two R and two C subunits.
Activation is achieved when cytoplasmic cAMP binds to
the R subunit, which then liberates the C subunit (110,
111). The RI subunit has a higher af®nity for cAMP
than RII a and b (112, 113) and a quicker turnover
(114). These observations suggest that PKAI and PKAII
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decode cAMP signals with different duration and
targets.
Classically, PKA activation promotes the phosphoryl-
ation of speci®c substrates such as CREB (cAMP
response element binding protein). CREB binds to speci®c
DNA sequences, called CREs, present in the promoters of
the genes that are required for the control of the growth
and differentiated phenotype in thyroid follicular cells
(26). Phosphorylation of CREB at Ser-133 (115) and
activation of cAMP-responsive genes occur within 15±
30 min of hormonal induction, coinciding with the time
required for PKA to reach the nuclear compartment
from the cytoplasm (116). In the continuous presence of
hormones, transcription of cAMP-responsive genes is
attenuated by protein phosphatase 1 (PP-1)-mediated,
and, in some cases, PP-2A-mediated, desphosphoryl-
ation of CREB at Ser-133. Indeed, PP-1 inhibitors such
as okadaic acid and the inhibitor-1 protein can reverse
the attenuation phase, thereby maintaining high levels
of phospho-CREB, and in consequence target gene
transcription. After the attenuation phase, there is a
refractory phase induced by progressive loss of PKA
activity as a consequence of C subunit protein down-
regulation (117). Proliferation and differentiation are
the most important effects of PKA activation. Thus,
CREB protein stimulates the expression of genes involved
in cell division such as c-fos and c-myc, two genes
induced by TSH and insulin in rat thyroid cell lines (47,
48). Data from in vivo and in vitro thyroid models suggest
the preferential role of PKAI subtype in the control of cell
proliferation (118). Microinjection of heat-stable PKA
inhibitor (PKI) in WRT cells partially inhibited the TSH/
cAMP-mediated DNA synthesis (119). Paradoxically,
microinjection of the PKA catalytic subunit failed to
stimulate proliferation (120), suggesting that there are
other PKA-independent signals that can contribute to
cAMP-stimulated cell cycle progression.
In parallel, PKA also has an important role in thyroid
differentiation, thus several thyroid speci®c genes
such as Tg, TPO, TSH-R, Na/Iÿ symporter (NIS) and
thyroid-speci®c transcription factors such as TTF-1,
TTF-2 and Pax-8 (121) are regulated by TSH/cAMP
(122), via PKA, and may be regulated by CREB or
members of the CREB family. Exclusion of the catalytic
PKA from the nucleus, after Ras transformation or PKC
activation, correlates with the loss of transcriptionally
active forms of TTF-1 and CREB proteins (123).
Conversely, overexpression of catalytic PKA or depletion
of the PKC reverses inhibition of Tg promoter activity by
Ras (124). These effects from PKA activity appear to be
mediated by a Ras-dependent delocalization and ulti-
mate loss of the PKAIIb isoenzyme (125), again
suggesting different functions for each PKA isoenzyme.
PKC
The PKC gene family is divided into three subgroups
based on sequence homology and cofactor requirements:
conventional PKCs (a, bI, bII and g) which are
dependent on Ca2+ for activation; non-conventional
PKCs (d, e, h and o) which are not dependent on Ca2+ for
activation, and atypical PKCs (z and l/i) which are not
stimulated by 1,2-diacylglycerol (DAG) or phorbol esters
and are Ca2+ independent (126). Classically, PKC
stimulation is dependent on inositol lipid hydrolysis.
Thus, stimulation of phospholipase C catalyzes the
hydrolysis of 4,5-bisphosphate (PIP2) and generates
inositol 1,4,5-trisphosphate (IP3) and 1,2-diacylglycerol
(DAG) (127). The resulting IP3 facilitates an increase in
intracellular Ca2+ (128), while DAG activates PKC (126).
Several pieces of evidence suggest that TSH plus insulin/
IGF-I can activate PKC by elevating DAG in FRTL-5 cells,
but this increase is independent of phospholipase C (PLC)
activation at normal TSH concentration (1±10 mU/ml)
(66, 129). The observation that TSH and its agonists
forskolin and dibutyryl-cAMP (dbcAMP) can activate
another phospholipase, PLD (responsible for the produc-
tion of DAG from phosphatidylcholine hydrolysis),
suggests an alternative mechanism for TSH-dependent
activation of PKC (130). The PLD activation depends on
PKA and PKC as has been demonstrated in experiments
with speci®c inhibitors of both kinases (131).
There is marked heterogeneity in PKC isoforms
among the thyroids of various species (132). When
FRTL-5 cells are chronically exposed to TSH, the a, d, e
and z PKC isoforms are expressed and all, except the last
isoform, are activated by phorbol esters (133). When
TSH-depleted FRTL-5 cells are stimulated with this
hormone there is no effect on the cytosolic fractions of
any of the PKC isoforms identi®ed, but the membrane-
bound fractions of a, e and zPKC after short-term
exposure, and of dPKC after long-term exposure do
increase (134). PKC isozymes are involved in signal
transduction pathways controlling growth, differentia-
tion and apoptosis (135, 136). In thyroid cells, PKC has
been implicated in differentiation, inhibiting TSH-
mediated increase in iodine uptake and organi®cation,
cAMP production (137, 138) and Tg (139), and 50 D-I
expression (139). Moreover, the expression of PKC
mimics the effects of Ras transformation, indicating a
possible role as an effector downstream from Ras (122,
140, 141). In FRTL-5 cells, activation of PKC by phorbol
esters have a mitogenic effect (67, 137). This effect
is cAMP independent and also inhibits TSH-mediated
cell growth, interfering with cAMP production (67).
Although phorbol esters are pharmacological agents,
their activation and effects may have a physiological
relevance in view of evidence that other physiological
agents, such as TSH, IGF-I or norepinephrine, may also
activate PKC in the thyroid cell, (66, 129, 142, 143).
PI3-kinase
Phosphoinositide-3-kinases (PI3-Ks) are a subfamily of
lipid kinases that catalyze the addition of a phosphate
molecule speci®cally to the third position of the inositol
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ring of phosphoinositide. To date, nine members of the
PI3-K family have been isolated in mammalian cells and
they are grouped into three classes according to the
molecules that they preferentially use as substrates
(144, 145). PI3-K was ®rst described as a PI-K activity
associated with the viral oncoproteins, v-Src, v-Ros, and
middle T polyomavirus. Mutational studies of these
oncoproteins indicated a critical role for their associated
PI3-K in cell transformation (146).
Usually, mitogenic signals that exert their action
through tyrosine kinase receptors stimulate PI3-K a/b
while those that activate G-protein-coupled receptors
stimulate PI3-Kg (147±150). PI3-K is required for the
mitogenic activity of many growth factors such as PDGF,
EGF and insulin. Most of these factors, speci®cally those
requiring PI3-K activity, stimulate lipid kinase activity.
The inactivation of this pathway by pharmacological
inhibitors or microinjection of PI3-K-speci®c inhibitory
antibodies or proteins (151±153) impairs growth
factor-stimulated mitogenesis. Although cAMP has
only been reported to inhibit PI3-K activity, these
studies were performed in cells where cAMP failed to
stimulate proliferation (154, 155). The biological effects
of PI3-K are mediated through downstream kinases
such as PDK1 (156±158), Akt (159±161), and p70s6k
(162, 163). The small GTPase Rac1 is also activated
downstream from PI3-K, where it contributes to p70s6k
activation and stimulates membrane ruf¯ing (164±
166). Recent reports using the WRT (167, 168) and
FRTL-5 (169) cell systems suggest the possible implica-
tion of PI3-K in the TSH/cAMP-dependent growth of
thyroid cells. Thus, TSH/cAMP stimulate membrane
ruf¯ing, Akt and p70s6k activity. Both the stimulation
of membrane ruf¯ing and Akt activity are PI3-K depen-
dent, whereas the stimulation of p70s6k activity is
PI3-K independent (although the possibility of some
p70s6k activation by PI3-K cannot be discarded). In
addition, treatment with the speci®c PI3-K inhibitor
wortmannin or the expression of a dominant negative
form of PI3-K causes a G1 arrest of FRTL-5 cells
stimulated to proliferate with TSH (169). Moreover,
TSH/cAMP increases p70s6k protein levels in a manner
that appears to be cAMP dependent but PI3-K
independent (167 and our unpublished observations).
In all these cases, PI3-K activation by TSH is exclusively
cAMP dependent and insulin independent because all
these observations were performed in cells that had
been arrested by the absence of insulin and TSH
and that had been restimulated with TSH alone
(168, 169).
Ras signaling and thyroid cells
General considerations Ras proteins are a group
of 20±25 kDa guanine nucleotide-binding proteins
that function as molecular switches in many cellular
signaling pathways. Thus, GTP-binding protein cycles
between the GDP-bound inactive state and the
GTP-bound active state. Activation is dependent on
external signaling and occurs when a guanine±
nucleotide exchange factor, GEF, accelerates nucleotide
release from the protein. Once activated, Ras proteins
can interact with the effector molecules generating a
signal pathway that involves a broad range of effectors.
Return to the inactive state is due to the GTP-binding
protein capacity to hydrolyze GTP to GDP, a GTPase
reaction that is accelerated by GTPase-activating
proteins (GAPs) which are either regulatory proteins
or can themselves be effectors (170±172).
In mammals, this superfamily of proteins is comprised
of over 60 members, which, based on sequence and
functional homology, can be divided into several
subfamilies: Ras, Rho, Rab, Arf, Ran and Rad/Gem.
The genes coding for these proteins are not only the
most frequently activated oncogenes in cancer, but their
corresponding proto-oncogenes are expressed in most
mammalian tissues. They codify proteins that interact
with a wide spectrum of regulators and downstream
effectors producing different normal cellular responses
such as proliferation, differentiation or apoptosis (173,
174). The expression of transforming Ras oncogenes
interacts with the establishment and the maintenance
of cellular differentiation in different tissues (175±178),
including the thyroid. In this particular tissue, Ras
inhibits the expression of thyroid-speci®c genes, and
confers a proliferative advantage over normal thyroid
cells (123±125, 140, 141).
Inhibition of thyroid differentiation by Ras The
growth of FRTL-5 cells transformed with a variety of
activated oncogenes such as v-ras, v-src, v-raf and
v-mos become TSH/cAMP independent. Furthermore,
the thyroid differentiation markers are suppressed and
so the transformed cells do not express Tg or TPO, do not
respond to TSH and do not take up iodine (25). In
parallel, the transcription factors controlling their
expression are either not present or are inactive (140,
179, 180). In K-Ras transformed cells, both Pax-8 and
TTF-1 mRNA are undetectable whereas in H-Ras, TTF-1
is present at normal levels and maintains its binding
capacity although the cells lack the ability to express Tg
and TPO (141). The mechanism inhibiting differentia-
tion after Ras activation appears to down-regulate the
catalytic PKA activity (123, 125). Inactivation of PKA
decreases the phosphorylation of transcription factors
such as TTF-1 and CREB, and inhibits the transcription
of speci®c genes such as Tg, TPO or TSH-R that contain
speci®c sites for these transcription factors (121, 124).
The accumulated results suggest that by activating PKC,
Ras ®nally inhibits the cAMP/PKA pathway The over-
expression of PKC mimics the effects on thyroid cell
differentiation exerted by the Ras transformation (124,
140, 141).
Ras effectors and mitogenesis Rat thyroid cell
proliferation is dependent on both PKA as well as Ras
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activation. Overexpression of a constitutive inactive Ras
form (Ras N17) signi®cantly reduces TSH-mediated
proliferation (120 and our unpublished observations).
Concomitant overexpression of Ras N17 and a consti-
tutive inactive PKA, fully suppress TSH-mediated pro-
liferation, suggesting that both PKA and Ras are
required for the full mitogenic action of TSH. Moreover,
these results suggest that Ras function may be crucial in
many G-protein-coupled signaling pathways in addition
to its established role in tyrosine kinase-mediated
pathways (120). Since TSH mitogenesis requires both
signals, these must interact in some way. In several cell
types in which intracellular cAMP levels inhibit growth,
this second messenger exerts a negative effect on Ras-
mediated signaling pathways. Several ®ndings suggest
that PKA inhibits the proper binding of Ras protein to
Raf, blocking the activation of the mitogen-activated
protein (MAP)/extracellular signal-regulated kinase
(ERK) kinase (MEK) and MAP kinases. In WRT cells,
an increase in cAMP levels inhibits coupling of Ras to
the Raf-dependent cytoplasmic kinase cascade (181±
183). In primary dog thyrocytes, MAP kinase phos-
phorylation is not implicated in TSH-mediated prolif-
eration (184). In FRTL-5 thyroid cells, the speci®c
inhibition of MEK by the inhibitor PD85059 does not
affect TSH-mediated proliferation (169). All these
®ndings suggest that the TSH pathway is Ras dependent
but Raf-1 and MEK independent and indicate that Ras
signaling in TSH-treated cells might occur through an
effector other than Raf. Some clues come from studies
with mutant Ras effectors which differ in their ability to
bind Raf (185). Thus, WRT cells overexpressing Ras
(12V) or Ras (35S), which lead Ras to bind Raf, grow
slowly in the presence of TSH, whereas another stable
transfectant overexpressing Ras (37G) which only binds
RalGDS, grows faster in the presence of TSH. These
results suggest a role for a nucleotide exchange factor
for Ral (RalGDS) in TSH-mediated proliferation. Several
groups have shown that RalGDS is a Ras effector (186,
187). Dominant negative Ral mutants can suppress the
oncogenic transformation induced by Ras in 50±75%
(188). This indicates that Ral activation by Ras±RalGDS
mediates some of the downstream effects of Ras,
although the functions of Ral have long remained
elusive (189). In WRT cells, microinjection of the
dominant negative RalA (RalA N28) reduces TSH-
and Ras-stimulated DNA synthesis (190). In addition,
RalGDS can bind Rap1, a small Ras-like GTPase,
identi®ed as a protein that could suppress the oncogenic
transformation of cells by Ras (188). Rap1 is activated
by several extracellular stimuli and is involved in
proliferation and differentiation. cAMP activates Rap1
in many cell types (191), including thyroid cells (168,
192), and cAMP-responsive Swiss 3T3 cells, where
Rap1 acts as a mitogen (193) and as an oncogen (191).
As we discussed before, recent reports have shown that
one component of cAMP action is the inhibition of MAP
kinase activation (194±196). Interestingly, the effects of
cAMP are very similar to those obtained after stable
expression of a positive dominant form of Rap1 called
Rap Val12. This mutant inhibits MAP kinase activation
(197). This information tempts us to speculate that
Rap1 plays a role in the cAMP-dependent inhibition of
the MAP kinase pathway. The mechanism of this
inhibition is unknown but one of the possible alter-
natives is that, upon activation, Rap may activate
speci®c phosphatases that affect the Ras pathway at the
Raf-1±MEK±MAP kinase activation step (191).
Although the microinjection of wild-type Rap1 fails to
induce proliferation or Tg expression in dog thyrocytes
(192), this point remains to be studied in more detail
using mutant forms of Rap1. All these recent ®ndings
open interesting questions about the effects of Rap1
overexpression on thyroid-speci®c markers under
normal or Ras-transformed situations.
Recently, two different groups have reported (198,
199) that activation of Rap1 by forskolin and cAMP
occurs independently of PKA. They cloned a gene
encoding a guanine-nucleotide-exchange factor (GEF),
called Epac (198), or cAMP-GEF (199), which contains
a cAMP-binding site and a domain that is homologous
to the GEF domain for Ras and Rap1. Thus, Epac seems
to be a GEF for Rap1 that is regulated directly by cAMP.
Epac is also expressed in the thyroid gland although its
role is unclear and remains to be clari®ed. Thus, in this
context, Epac may have an important function in the
activation of proliferative or differentiative programs
that are mediated by cAMP but are independent of
PKA.
Rho family and thyroid The mammalian Rho family
of GTPases, including RhoA, Rac1, and Cdc42, play
pivotal roles in controlling many cellular functions,
such as cell polarity, motility, proliferation, apoptosis,
and cytokinesis (200). RhoA controls the assembly of
actin stress ®ber and focal adhesion complexes, Rac
regulates actin ®lament accumulation at the plasma
membrane to produce lamellipodia and membrane
ruf¯es, and Cdc42 stimulates the formation of ®lopodia
(201, 202). All these proteins also stimulate progres-
sion through phases G1 to S of the cell cycle and their
inhibitor forms can block serum-induced DNA synthesis
(203). Rac1 and Cdc42 stimulate the JNK±SAPK
cascade and lead to c-Jun transcriptional activity
(204). RhoA is also involved in serum response factor
(SRF) activation and acts synergistically with Rac1 and
Cdc42 through a JNK-independent pathway (205).
All three proteins, Rho, Rac and Cdc42, cooperate
with Raf in cell transformation and the dominant
negative forms of RhoA, RhoB and Rac1 can inhibit
Ras-induced transformation, indicating an essential role
for these proteins in this process (206±210). Moreover,
Rac1 and RhoA have also been implicated in the
morphogenic and mitogenic responses to transforma-
tion by oncogenic Ras (165, 211). In the thyroid
context, Cass et al. (168) described that activation of
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Rac1 by a PKA-independent pathway, via PI3 kinase
after TSH/cAMP stimulation, promotes the formation of
ruf¯es on WRT thyroid cells.
In several cell types, such as neural cells and
lymphocytes, RhoA can be speci®cally phosphorylated
at Ser-188 by PKA. This effect decreases the binding of
RhoA to the downstream effector ROKa, suggesting
that RhoA and cAMP have antagonistic roles in
regulating cellular processes in these cells (212, 213).
However, the role of cAMP is completely different in the
thyroidal context. This second messenger activates a
proliferative response in most of the thyroid cells
systems studied. Noguchi et al. (214) suggest that
RhoA activation after growth stimulation plays an
essential role in the degradation of p27Kip1 with the
resulting progression from phase G1 to S in FRTL-5
cells. RhoA is geranylgeranylated and translocated to
the membrane during this progression. Moreover, its
activation is dependent on 3-hydroxy-3-methylglutaryl
coenzyme A reductase (HMG-CoA-Red), the rate-limit-
ing enzyme for the synthesis of isoprenoids such as the
geranylgeranyl metabolites (215). This enzyme is tran-
scriptionally regulated by TSH in FRTL-5 cells (216,
217). Results from our laboratory con®rm the impor-
tant role of RhoA in the control of TSH-mediated
proliferation. Thus, overexpression of either the domi-
nant negative form RhoA N19 or the speci®c inhibitor
of RhoA activity, exoenzyme C3 (TC3), inhibits the
FRTL-5 cells proliferation causing a G1 arrest. More-
over, the TSH-mediated activation of RhoA protein is
PKA/HMG-CoA-Red dependent (169). The upstream
regulators of RhoA are unknown but some authors,
studying other cell systems, have proposed that Ras
could activate RhoA-like proteins through its down-
stream effector RalGDS (218). Figure 1 presents a
summary of our view on signaling in thyroid cells after
the integration of the most recent observations.
G1 phase progression in thyroid cells
Key regulators of G1 progression in mammalian cells
include three D-type cyclins (D1, D2 and D3), which
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Figure 1 Hypothetical model of the signal transduction pathways induced by TSH and Insulin/IGF-I. TSH increases cAMP intracellular
levels and eventually could activate Ras pathways. cAMP exerts its action through PKA-dependent and -independent pathways such as the
cAMP±GEF (Epac) and PI3-K. All these pathways activate different downstream effectors that might interact with others pathways. In
parallel, insulin activates Ras pathways and its downstream effectors (Raf, RalGDS and PI3-K). Finally all these pathways regulate several
biological processes such as proliferation, differentiation and cytoskeletal remodeling. Symbols: arrows, activation; blocked bars, inhibition;
dashed arrows, eventual pathways.
assemble into holoenzymes with either CDK4 or CDK6,
and cyclin E, which combines with CDK2 and is
expressed weakly at the G1±S boundary (219). The
timing and periodicity of cyclin E expression in mam-
malian cells suggest that this cyclin may control the
ability of the cells to enter into the S phase. Over-
expression of D- or E-type cyclins can reduce the G1
phase, decrease cell size, and reduce the dependency of
the cell on mitogens (220±222). Induction of D-type
cyclin synthesis is strongly dependent on growth factors
and D-cyclin levels decline precipitously when growth
factors are withdrawn (223±225). Mitogen-induced
Ras signaling promotes transcription and assembly of
the cyclin D1 with CDK4 via Raf/MAPK (226±229).
The degradation of D-type cyclins depends on a separate
Ras signaling pathway involving PI3-K and Akt (230).
These data suggest that D-type cyclins act primarily as
growth factor sensors.
The D-type cyclins (231, 232), target CDK4 to Rb
(233) and, unlike most CDKs, cyclin D-CDK4/6 phos-
phorylates Rb preferentially to histone H1 (234, 235).
Rb binds to E2F-DP1 heterodimers and negatively
regulates the activities of these transcription factors,
with important functions in the G1±S transition.
Phosphorylation of Rb on canonical CDK sites during
middle to late G1 phase reverses the growth-suppressive
effects of Rb by releasing E2F from its inhibitory
constraint, thereby enabling the liberated factor to
activate the genes required for DNA replication (236).
Meanwhile, cyclin E preferentially forms complexes with
CDK2 that phosphorylate substrates such as (i) histone
H1 (237, 238), (ii) Rb (on sites other than where it is
phosphorylated by D-CDK4/6) (239±243), (iii) the CDK
inhibitor p27Kip1 (244, 245), and (iv) possibly other
substrates that help trigger the ®ring of replication
origins (246±251) during late G1 and early S phase (see
Fig. 2). Once cells enter the S phase, cyclin E is degraded
and CDK2 forms complex with cyclin A. The cyclin
E±CDK2 and cyclin D±CDK4/6 complexes undergo
phosphorylation on a single threonine residue, a
modi®cation required for their activation. This activa-
tion involves a multisubunit enzyme designated CDK-
activating kinase (CAK) composed of a catalytic subunit
(CDK7) and a novel cyclin (cyclin H) (252).
In FRTL-5 cells, TSH, IGF-I, or a combination of both,
induce G1 cyclin (D1, D3, and E) expression and
accelerate the G1 phase (40, 92, 253). In quiescent
FRTL-5 cells, levels of cyclin D1 and E are barely
detectable; however, 24 h after TSH stimulation, their
expression increases several fold (254). Stimulating
growth in quiescent FRTL-5 cells with TSH, IGF-I and
5% calf serum results in an increase of CDK4 and CDK2
expression, and correlates with an increase in the
phosphorylated form of Rb, all of which lead to cell cycle
progression (92, 254). Moreover, results from our
laboratory (169) indicate that the stimulation of
quiescent FRTL-5 cells with TSH alone also increases
both the expression levels of G1 cyclins (D1 and E) and
CDK2 as well as the phosphorylation status of Rb. These
results suggest that TSH increases the assembly and
activity of cyclin D±CDK4 and cyclin E±CDK2 com-
plexes. This is demonstrated by the increase of both
CDK2 kinase activity (measured in vitro using histone
H1 as a substrate) and Rb phosphorylation (measured
as indirect index of cyclin D±CDK4 activity).
Another level of CDK regulation comes from the
binding of CDK inhibitors (CKIs) to cyclin±CDK com-
plexes that then either inhibit their kinase activities or
prevent their activation by CAK (6). The CKIs comprise
two classes of proteins, the Ink4 family, which speci-
®cally inhibits cyclin D-dependent kinases, and the Cip/
Kip family, which can interact with virtually any cyclin±
CDK complex. The Ink4 family includes 15±20 kDa
proteins composed of repeated, loosely conserved
ankyrin motif (1). The expression of p15Ink4b is induced
almost 30-fold in human keratinocytes treated with
TGF-b. This induction is correlated with an increase of
p15Ink4b binding to CDK4/6 resulting in a loss of activity
(2). These ®ndings suggest that p15Ink4b has a role as
dominant effector of TGF-b-mediated cell cycle arrest in
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Figure 2 Regulation of the G1±S transition.
Mitogenic signals promote the assembly of active
cyclin D-dependent kinases containing either
CDK4 or a Cip/Kip protein. Sequestration of Cip/
Kip proteins lowers the inhibitory threshold and
facilitates activation of the cyclin E±CDK2 com-
plexes. Both cyclin D and E contribute sequen-
tially to Rb phosphorylation, canceling its ability to
repress E2F family members and activating
genes required for entry into S phase. The latter
includes cyclins E and A, as well as a set of
important genes that regulate DNA synthesis (for
review see Nevins 1992, 236). Moreover, cyclin
E±CDK2 complexes can phosphorylate p27Kip1
triggering its proteolysis. The degradation of Cip/
Kip proteins and the induction of cyclins by E2F
(positive feedback) contribute to mitogen inde-
pendence and to the irreversibility of the transition
(modi®ed from Sherr & Roberts 1999, 6). Sym-
bols: arrows, activation; blocked bars, inhibition.
these cells. Thus, it has been proposed that TGF-b
treatment induces the p15Ink4b expression that shifts
p27Kip1 from cyclin D±CDK4/6 to cyclin E±CDK2
complexes (255). In FRTL-5 cells this mechanism has
not been implicated among the known TGF-b effects
and seems to be more related with the loss of p27Kip1-
free cyclin D±CDK4/6 complexes that leads to the shift
of free p27Kip1 to cyclin E±CDK2 and its consequent
inactivation (92).
The Cip/Kip family comprises p21, p27 and p57 gene
products. These CKIs can interact with many different
cyclin±CDK complexes, raising the possibility that they
might act as a cyclin±CDK assembly factor. While
cyclin±CDK complexes containing a single molecule of
this family are catalytically active, those containing
multiple molecules are not. Thus, changes in the
stoichiometry of CKIs are suf®cient to modulate the
complex activation (256). Although several CKIs have
been identi®ed as potent inhibitors of cyclin±CDK
complexes, p27Kip1 is the only CKI whose protein
expression decreases when mitogen-induced cells enter
the cell cycle (257±260). p27Kip1 levels are elevated in
quiescent cells and decline during the G0±S phase
interval (260, 261). If the synthesis of CDK4 is inhibited
by TGF-b treatment, the free p27Kip1 levels inhibit cyclin
E±CDK2 kinase activity and induce G1 arrest. Hence
titration of p27Kip1 by cyclin D±CDK4/6 may promote
cyclin±CDK2 kinase activity and help to establish the
order of activation (13, 232). The decrease of p27Kip1
expression occurs through protein degradation via the
ubiquitin±proteasome pathway (262). The existence
of inhibitory levels of p27Kip1 appears to be involved in
the growth-inhibitory properties of TGF-b, rapamycin,
and cAMP (13, 14, 261). In contrast, overexpression of
p27Kip1 antisense cDNA results in mitogen-independent
G1 progression, demonstrating the importance of p27Kip1
for maintaining cell quiescence (263, 264). Although
the mitogenic signals responsible for p27Kip1 degrada-
tion have not been de®ned clearly, in Chinese hamster
embryo ®broblast cells (IIC9 cells) PDGF stimulation
causes the rapid activation of Ras and subsequent
downstream activation of ERK (227, 265). In addition,
Ras also stimulates the downstream activation of the
RhoA that regulates p27Kip1 degradation to ensure the
proper activation state of cyclin D1±CDK4 complexes
following mitogenic stimulation (265). Interestingly, in
thyroid cells where the cAMP is mitogenic, TSH stimu-
lation down-regulates p27Kip1 and this effect correlates
with an increases in cell proliferation (40). TSH down-
regulation of p27Kip1 appears to be mediated by the
activation of RhoA protein after growth stimulation in
FRTL-5 (254). These data indicate the important
differences of cAMP signaling and the existence of
speci®c circuits in different cell types.
Concluding remarks
In this work we have given an overview of the complex
regulation of thyroid growth based on data accumu-
lated using rat thyroid cell systems as an experimental
model. These useful cell lines let us probe deeply into the
main signal transduction pathways and cell cycle-
related genes implicated in TSH-mediated proliferation
of thyroid cells. The data basically describe two main
pathways involved in TSH/cAMP-mediated proliferation
in rat thyroid cells, one that is PKA dependent and
another that is PKA independent. The ®rst pathway
could implicate the small GTPase RhoA whereas the
second one could involve Rac1 and Akt activation
through PI3-K. On the other hand, TSH/cAMP can
activate the p70s6k phosphorylation necessary for rat
thyroid cell growth. The role of Ras in this context must
be clari®ed, since this protein is necessary for TSH-
mediated proliferation although no direct activation of
Ras after TSH treatment has yet been demonstrated.
Moreover, the hierarchy of activation of the small
GTPases, their downstream effectors, and possible
crosstalk between different pathways remain elusive.
To complicate the puzzle, the new cAMP±GEFs, which
are also expressed in thyroid tissue, might have a role in
cAMP-mediated proliferation that bypasses PKA and
directly targets cAMP signal to small GTPases such as
Rap1. The activation of these pathways ®nally con-
verges and activates target genes involved in thyroid
differentiation and cell cycle-related genes required for
the G1±S phase transition.
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